Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein L32 pseudogene 23 (RPL32P23)
- Target
- RPL32P23
- Molecular classification
- Other (Processed pseudogene)
01
Overview
Ribosomal protein L32 pseudogene 23 is a processed pseudogene of the functional RPL32 gene. While it does not code for a protein product, its sequence is present in the human genome and is recognized by standard gene annotation consortia. Pseudogenes like RPL32P23 are generally non-functional in terms of protein synthesis but may occasionally adopt RNA regulatory roles, as shown in certain tumor contexts for related pseudogenes (e.g., RPL32P3). There is no direct evidence implicating RPL32P23 in disease, drug interactions, or established cellular pathways, and it is typically classified as “Other” in molecular classification schemes.
- Other names
- RPL32_6_1020RPL32P23
02
Biological functions
Regulation of gene expression via non-coding RNA mechanisms (for some pseudogenes; specific evidence for RPL32P3, a closely related pseudogene, but not for RPL32P23 itself)Likely considered “Other” unless direct evidence is shown for RPL32P23
03
Disease associations
Other (No direct evidence for involvement of RPL32P23 in any disease; studies on RPL32P3, a different pseudogene, show regulatory effects in glioma models)
Beyond the preview
Go deeper on Ribosomal protein L32 pseudogene 23 (RPL32P23).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ribosomal protein L32 pseudogene 23 (RPL32P23).